To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
8,334 Current news from the industry pharmarss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
CureVac AG announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and GSK ...
Further Development of a New Generation of Antibody-Drug Conjugates
Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tech ...
Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets
Evotec SE announced that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH, a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing ...
Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements ...
Doses expected to be delivered in 2020 and 2021
Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not ...
Marinomed is now planning clinical tests using the same technology for an inhalation solution that could also work in the lungs
Marinomed Biotech AG announces that pre-clinical data show that Carragelose® has the potential to reduce the risk of an infection with SARS-CoV-2 and may also treat COVID-19. Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the ...
Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group
Based on the strong performance of the Bioprocess Solutions Division in the first half of 2020 as well as on high demand also expected to continue for the rest of the current fiscal year, Sartorius raised its full-year sales and earnings guidance for this division and thus for the entire Group. ...
Belén Garijo appointed Vice Chairman of the Executive Board and Deputy CEO
The Board of Partners of E.MerckKG appointed Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO of Merck KGaA. She will maintain her current Executive Board responsibilities. “The appointment of Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO recognizes her ...
The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that ...
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body. The study, which will ...